详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

PTPMT1 regulates mitochondrial death through the SLC25A6-NDUFS2 axis in pancreatic cancer cells

67| 认领 | 导出 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Gastroenterology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, P. R. China [2]Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, P. R. China [3]Department of Gastroenterology, The First Medical Center of PLA General Hospital, Beijing 100853, P. R. China [4]Department of Experimental Hematology and Biochemistry, Beijing Institute of Radiation Medicine, Beijing 100850, P. R. China

出处：

ISSN：

关键词： Pancreatic ductal adenocarcinoma PTPMT1 alexidine dihydrochloride

摘要：

Pancreatic ductal adenocarcinoma is a highly malignant cancer with poor prognosis, for which effective therapeutic strategies are urgently needed. The dual-specificity phosphatase PTPMT1 is localized in mitochondria and highly expressed in various cancers. Here, we investigated the function of PTPMT1 in pancreatic ductal adenocarcinoma. We inhibited its expression in pancreatic cancer cell lines using siRNAs or the specific PTPMT1 inhibitor alexidine dihydrochloride and observed that PTPMT1 silencing in pancreatic cancer cell lines drastically reduced cell viability, caused mitochondrial damage, and impaired mitochondrial function. Co-immunoprecipitation analysis demonstrated that PTPMT1 could interact with SLC25A6 and NDUFS2, indicating that it may modulate mitochondrial function via the SLC25A6-NDUFS2 axis. Collecively, our data highlight PTPMT1 as an important factor in pancreatic ductal adenocarcinoma and a potential therapeutic target.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.6 最新[2023版] 4.5 最新五年平均 5.942 出版当年[2021版] 6.083 出版当年五年平均 6.166 出版前一年[2020版] 5.3 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Gastroenterology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, P. R. China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Gastroenterology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, P. R. China [2]Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, P. R. China [4]Department of Experimental Hematology and Biochemistry, Beijing Institute of Radiation Medicine, Beijing 100850, P. R. China [*1]Department of Gastroenterology, Beijing Shijitan Hospital of Capital Medical University, No. 10 Tieyi Road, Haidian District, Beijing 100038, P. R. China [*2]Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, P. R. China. [*3]Department of Experimental Hematology and Bio-chemistry, Beijing Institute of Radiation Medicine, Beijing 100850, P. R. China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]圆柱瘤蛋白在胰腺导管腺癌组织中的表达及在预后评价中的作用 [2]HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival [3]孤儿核受体在胰腺癌中的表达及临床意义的研究 [4]Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by transferring miR-100-5p. [5]Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression [6]间充质干细胞来源的外泌体转运微小RNA-145-5p对胰腺癌细胞的影响 [7]Ultrasound microbubble targeted gemcitabine delivery for pancreatic cancer treatment [8]Ultrasound Microbubble Targeted Gemcitabine Delivery for Pancreatic Cancer Treatment [9]Ultrasound Microbubble Targeted Gemcitabine Delivery for Pancreatic Cancer Treatment [10]人脐带间充质干细胞来源的外泌体通过miRNAs促进胰腺癌细胞生长